AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01568008 — intervention group
Intervention type: DRUG
Intervention: Bimatoprost 0.01% ophthalmic solution
Description: Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
Study NCT02202993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibefradil with Radiation
Description: Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy.
Study NCT03562611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine administration during surgery
Study NCT03562611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Axetil
Description: Flurbiprofen axetil administration during surgery
Study NCT03562611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine and Flurbiprofen Axetil
Description: Nalbuphine and Flurbiprofen Axetil administration during surgery
Study NCT02693171 — intervention group
Intervention type: DRUG
Intervention: Dinutuximab
Description: Unituxin was administered along with cytokines according to the prescribing information
Study NCT03342027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: medication for smoking cessation
Study NCT03342027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively smoke free
Description: an 8 session, tailored behavioral intervention for treating tobacco dependence
Study NCT03342027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief advice to quit smoking
Description: Standardized brief advice to quit smoking (standard of care)
Study NCT03342027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brief advice to quit smoking
Description: Standardized brief advice to quit smoking (standard of care)
Study NCT03244540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP (transversus abdominis plane block)
Description: ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
Study NCT03244540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB (quadratus lumborum block)
Description: ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
Study NCT03244540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimuplex Ultra 360 needle
Description: ultrasound-guided needle will be used for QLB and TAP and regional blocks
Study NCT03244540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)
Study NCT03244540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study NCT04032041 — intervention group
Intervention type: DEVICE
Intervention: Structure Sensor
Description: A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
Study NCT04032041 — intervention group
Intervention type: DEVICE
Intervention: Caliper
Description: Caliper: An OriginCal IP54 digital caliper (Anytime Inc, Granada Hills, CA) was used to take three consecutive physical measurements in millimeters at each identified measurement location. For measurements outside of the caliper's scope a tape measure was used in place of the caliper. Physical measuring devices were reset to zero between each measure.
Study NCT02411656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02411656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03362476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based alcohol reduction intervention
Description: Brief computer-based version of motivation enhancement therapy (MET) used in conjunction with clinician-delivered MET and standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
Study NCT03362476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief clinician-delivered MET
Description: Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
Study NCT03362476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief clinician-delivered MET
Description: Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
Study NCT03362476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
Study NCT03362476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
Study NCT03164148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-REX TRI00A
Description: Case management consists of confirmation of hospital visit date, checking the adverse effect
Study NCT03244540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subarachnoid anesthesia
Description: subarachnoid anesthesia for each patients participating in the study with pencil point needle
Study NCT02599870 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NeuroIDgenetix Test Panel
Description: The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
Study NCT04249362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
Study NCT03139383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dextrose solution
Description: The patients received 5%D/N/2 during surgery
Study NCT03139383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: The patients received NSS during surgery
Study NCT02764788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific auriculotherapy
Description: Specific auriculotherapy with needles
Study NCT01834443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct current galvanic vestibular stimulation
Study NCT01834443 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct current galvanic vestibular stimulation
Study NCT04540107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV
Study NCT04540107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04540107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study NCT00884754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope rigid stylet
Description: Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
Study NCT00884754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope rigid stylet
Description: Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
Study NCT01087996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto-hMSCs
Description: Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
Study NCT01087996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
Study NCT03244540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCA (patient controlled analgesia)
Description: All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
Study NCT02411838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.~Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI \<28 will follow a regimen of fasting for two days per week while patients with BMI>28 will follow a regimen of fasting for three days per week.
Study NCT02500459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
Study NCT02500459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter
Description: The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
Study NCT00903734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride (Tarceva)
Description: Dose of 150 mg daily by mouth.
Study NCT02764788 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-specific auriculotherapy
Description: non-specific auriculotherapy with needles
Study NCT02764788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: seed auriculotherapy
Description: non-specific auriculotherapy with seeds
Study NCT03916601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR341402
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT03916601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Pharmaceutical form: suspension for injection~Route of administration: subcutaneous
Study NCT03916601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR341402
Description: Pharmaceutical form: suspension for injection~Route of administration: subcutaneous
Study NCT03244540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
Study NCT03244540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Study NCT03244540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
Study NCT01925066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Study NCT00287989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00287989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150mg
Study NCT00287989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200mg/m2
Study NCT00287989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 1500mg
Study NCT04592237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV
Study NCT04592237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04592237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Given IV
Study NCT04592237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT04554940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vosoritide
Description: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Study NCT02568267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: TrkA/B/C, ROS1, and ALK inhibitor
Study NCT01053377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamiflu (verum)
Study NCT01053377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamiflu placebo
Study NCT03186482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Descovy® (TAF/FTC)
Description: 25/200 mg once daily for 28 days (DAYS 1-28).
Study NCT03186482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread® (TDF)
Description: 245 mg once daily for 28 days (DAYS 57-84).
Study NCT03186482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifadin® (Rifampicin)
Description: 600 mg once daily for 28 days (DAYS 29-56).
Study NCT06127576 — intervention group
Intervention type: DEVICE
Intervention: paraboloid geometry double and triple dental abutment-implant
Description: The implants were inserted with the margin between machined and micro-rough surface at bone level. The abutment and crowns were assembled and screw retained onto the implant with a torque of 35 Ncm.~The implants were cylindrical with internal hexagon and without surface treatment, presenting 4.0 mm in diameter and length varying between 10 and 13 mm.~Acording to the manual work model measurements, DA or TA acrylic individualized design and paraboloid surfaces of the DA (elliptical) and TA (hyperbolic) had been made.
Study NCT02653638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation
Study NCT02653638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation
Study NCT03895489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Journey II
Description: Smith and Nephew Richards (SNR) Journey II Knee prosthesis
Study NCT03895489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker
Description: Stryker Triathlon Total Knee prosthesis
Study NCT03895489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer
Description: Zimmer Persona® The Personalized Knee prosthesis
Study NCT03192644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAI
Description: transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Study NCT03192644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
Study NCT03192644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidoxorubicin and cisplatin and lipiodol
Description: epidoxorubicin and cisplatin and lipiodol
Study NCT03192644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Description: oxaliplatin, calcium folinate, and 5-FU
Study NCT02290002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Dobesilate
Description: 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
Study NCT02290002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coasting
Description: In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
Study NCT03510624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebaudioside A
Description: Rebaudioside A 3g
Study NCT04411979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment-as-usual plus aerobic walking
Description: aerobic walking
Study NCT03510624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Empty capsules
Study NCT01125722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive neurostimulation device
Description: Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
Study NCT01125722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive neurostimulation device
Description: Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
Study NCT01575743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercising
Description: All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
Study NCT01575743 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic exercising
Description: All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
Study NCT04064970 — intervention group
Intervention type: BEHAVIORAL
Intervention: patient acceptable symptom state (PASS)
Description: The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
Study NCT03429244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET-MRI
Description: Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.